Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0487-0111 in Type 2 Diabetes
NCT07535307Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amycretin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change in M-value in Hyperinsulinaemic euglycaemic clamp (HEC) at 40 weeks. Started Apr 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07535307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535307.